Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05259527 · ClinicalTrials.gov registry record · Phase 2
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
A Phase 2 study of Neuropathic Pain, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05259527 is a Phase 2 study of Neuropathic Pain that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 120 participants, above the 98-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (22% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05259527, a Phase 2 study of Neuropathic Pain, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a two-arm randomized clinical trial in which 80 participants with Vitamin D deficiency and scheduled to begin taxane-based chemotherapy will be randomized to either: 1) prescribed vitamin D replacement or 2) standard of care.
Conditions Studied
Interventions
- DRUG Ergocalciferol Capsules
- DIETARY_SUPPLEMENT Cholecalciferol Capsules
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05259527
The ClinicalTrials.gov registry entry for NCT05259527 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 98-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (22% higher). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Ergocalciferol Capsules is the first listed.
NCT05259527 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05259527 about?
NCT05259527 is a clinical study titled "Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy". This is a two-arm randomized clinical trial in which 80 participants with Vitamin D deficiency and scheduled to begin taxane-based chemotherapy will be randomized to either: 1) prescribed vitamin D replacement or 2) standard of care.
What is the current status of trial NCT05259527?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-12-19. Estimated completion is 2030-03-31.
What conditions does trial NCT05259527 study?
This clinical trial studies the following conditions: Neuropathic Pain.
What interventions are being tested in trial NCT05259527?
The interventions under investigation include: Ergocalciferol Capsules (DRUG), Cholecalciferol Capsules (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05259527?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05259527 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
RECRUITING · Phase 2
-
Ginger Root Extract for Sciatic Pain Individuals
RECRUITING · Phase 2
-
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 2
-
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
COMPLETED · Phase 2
-
BMS-741672 for Diabetic Neuropathic Pain
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.